# European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients

> **NCT00217763** · PHASE3 · UNKNOWN · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 930 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** 3APS

## Key facts

- **NCT ID:** NCT00217763
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 930 (ESTIMATED)
- **Last updated:** 2007-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217763, "European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00217763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*